SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Addition of immunotherapy to perioperative chemotherapy for resectable gastric and gastroesophageal junction cancer: A meta-analysis of phase 2/3 trials
Provisionally accepted
- 1Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University, Nanning, China
- 2The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
- 3China Pharmaceutical University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: The integration of immune checkpoint inhibitors (ICIs) with perioperative chemotherapy (CT) has become a major focus of clinical research in resectable gastric or gastroesophageal junction (G/GEJ) cancer. Recent phase 2 and 3 trials have reported disparate outcomes, generating considerable debate. To synthesize this evidence, we conducted a meta-analysis to evaluate the efficacy and safety of adding ICIs to CT in this setting. Methods: A systematic literature search of PubMed and major conference proceedings was conducted up to August 15, 2025. Efficacy outcomes included summary relative risks (RRs) for pathological complete response (pCR) and R0 resection rate, and hazard ratios (HRs) for event-free survival (EFS) and overall survival (OS). Safety was assessed using RRs for treatment-related adverse events (AEs). Results: Four trials (one phase 2 [NEOSUMMIT-01], one phase 2/3 [DANTE], and two phase 3 [KEYNOTE-585, MATTERHORN]), encompassing 2,358 patients, were included. The addition of ICIs to CT significantly improved pCR (RR: 2.80; 95% CI: 1.68–4.67), EFS (HR: 0.76; 95% CI: 0.67– 0.87), and OS (HR: 0.78; 95% CI: 0.61–0.99), although it did not increase the R0 resection rate. Regarding safety, the combination did not increase the risk of overall grade 3-5 treatment-related AEs. However, it was associated with a significantly higher risk of grade 3-5 immune-related AEs (RR: 2.88; 95% CI: 1.95–4.24) and treatment-related serious AEs (RR: 1.14; 95% CI: 1.01–1.28). Conclusion: The addition of ICIs to perioperative CT confers significant improvements in pCR, EFS, and OS in resectable G/GEJ cancer, with a generally manageable safety profile. However, longer follow-up is required to validate survival benefits, and the increased risk of immune-related toxicity underscores the need for administration in specialized centers. These findings suggest that perioperative chemo-immunotherapy is a promising treatment strategy, though its definitive role awaits confirmation from ongoing phase 3 trials.
Keywords: immune checkpoint inhibitors, chemotherapy, gastric cancer, Perioperative treatment, Meta-analysis
Received: 25 Aug 2025; Accepted: 03 Nov 2025.
Copyright: © 2025 Lin, Liao and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuxuan Lin, yxuan_lin@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.